Navigation Links
The Chiesi Group Lands in the United States
Date:5/7/2009

ris and Rockville (USA), in 2008 the company added Chippenham (UK) which has set itself the objective of innovating in the field of pressurised aerosols.

There are 3,243 people working for Chiesi, of whom more than 300 are employed in research. Last year, the Group's work force grew by 10%, with new hires mainly in Italy, Spain, Eastern Europe, Russia, Greece and in the new subsidiaries in the Netherlands, Turkey and China.

Cornerstone Profile

Cornerstone Therapeutics Inc. (NASDAQ CM: CRTX), headquartered in Cary, N.C., is a pharmaceutical company focusing on the acquisition, development and marketing of prescription drugs for the respiratory therapeutics area. The company, which in 2008 had revenues of 64.9 million dollars, a 131% increase over 2007, is currently promoting non-proprietary drugs in the United States; it has its own marketing network selling to specialists in respiratory illnesses and the main pharmacies. In addition, Cornerstone, which in 2008 invested about 3.8 million dollars in R&D, has a pipeline of molecules in the advanced clinical phase; thanks to these, it plans to submit some new products to the registration procedure in the next three years. Cornerstone's marketing strategy consists of increasing its market share for those products it is marketing through its own marketing and promotional skills, of acquiring new pharmaceutical products and of maximising the value of the products currently marketed, as soon as they are acquired, or of the drug candidates under development.


'/>"/>
SOURCE Chiesi Farmaceutici S.p.A.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Simcere Pharmaceutical Group to Announce 2009 First Quarter Earnings on Monday, May 18, 2009
2. DuPont Statement on Obama Administration Biofuels Interagency Working Group
3. The Arcas Group Appoints Executive Vice President
4. Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury
5. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
6. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
7. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
8. Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors
9. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
10. Disabled and other vulnerable groups more susceptible to terrorism fears
11. ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") today ... research program with Emerald Logic, a leader ... Technology (FACET), Emerald Logic analyzed Resverlogix,s complete ... each of 798 patients who participated in ... SUSTAIN and ASSURE. The objective of this ...
(Date:3/4/2015)... Irvine, CA (PRWEB) March 04, 2015 ... research leader in Personalized Medicine, is excited to ... “Incorporating Genetic Testing to Optimize the Management of ... be available at Medscape.com for the next year. ... medical professionals how to recognize inadequate pain treatments, ...
(Date:3/4/2015)... , March 4, 2015  BioClinica®, ... and technology provider, today announced that clinical ... countries convened at its annual European User ... to discuss the use of its ... BioClinica,s eClinical technologies include: the Microsoft Office-Smart ...
(Date:3/4/2015)... March 04, 2015 Follow us ... one of the fastest growing technologies in the life ... subcellular visualization is driving growth in nucleic acid detection ... understanding of gene expressions will continue to benefit the ... in fields ranging from pharma, biotech, food & beverage ...
Breaking Biology Technology:Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4
... YORK, Nov. 11, 2010 Oligomerix, Inc. today announced ... (SBIR) Phase II grant for $1.6M from the National ... a program to discover small molecules and antibodies targeting ... therapeutics for Alzheimer,s disease. Compound libraries will be screened ...
... 2010 StemCyte, Inc., one of the world,s preeminent ... proud to announce that the Company has been awarded ... Revenue Service,s Qualifying Therapeutic Discovery Project (QTDP) program designed ... 250 employees. The Patient Protection and Affordable ...
... Nov. 11, 2010 Wound Management Technologies, Inc., (OTC ... advanced wound care solutions, announced today that its President, ... widely-acclaimed wound care product, CellerateRX®, recent strategic developments, and ... Investors Conference to be held at the JW Marriott ...
Cached Biology Technology:Oligomerix, Inc. Awarded Phase II NIH Grant to Discover Novel Drugs for Alzheimer's Disease 2StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP) 2Wound Management Technologies to Present at LifeTech Capital Miami Medical Investors Conference 2
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ... A Global Market Overview" report to their offering. ... to ensure that an individual is who she/he is claiming ... use of a person,s unique physical characteristics, such as fingerprint, ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... the game was designed to make a lefty the ... Douglas Professor of Engineering at Washington University in St. ... mechanical engineer who specializes in aircraft and helicopter engineering ... Pastime. First of all, some numbers. "Ninety percent of ...
... from UC San Diego are collaborating with scientists ... to map patterns of biodiversity and land use ... combined with climate models, will project how climate ... policy for setting aside conservation easements. Wildlife, ...
... interview with a researcher, please contact the Communications and External ... For more information on ORNL and its research and development ... you have a general media-related question or comment, you can ... ENERGY -- Spent fuel pellets . . . ...
Cached Biology News:Baseball diamonds: the lefthander's best friend 2Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 2Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 3Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 3
... Super Sensitive MultiLink IHC Detection ... secondary antibodies, labeled with multiple ... the bound primary antibody, and ... Streptavidin-Enzyme conjugate. This kit is ...
Sf21 Insect Cells (Live) in Max-XP Medium...
EZ-DeWax is a one-step solution that simultanously removes paraffin from and rehydrates formalin-fixed, paraffin embedded tissue...
... unit is an inexpensive personal or mini thermal ... process. Lightweight, with a small footprint, it can ... the researcher's desk. , The Gene Cycler thermal ... not have access to a large laboratory thermal ...
Biology Products: